Nathan Moser, Sr. expects GDP to surprise to the upside next year and makes the bull case for U.S. small caps. He especially sees opportunities in biotech and shares several picks, including Pacira Biosciences (PCRX) and SI-Bone (SIBN). “Many of the great medtech companies are eventually acquired,” he notes as well.